Table 3.
Co-occurrence of gene alteration in cancer cohorts with STAT3/CDK2/2/4/6 genetic alteration.
| S/N | Genes ID | Cytoband | Altered Group | Unaltered Group | Log Ratio | p-Value | q-Value | Enriched in |
|---|---|---|---|---|---|---|---|---|
| Cyclin Dependent Kinase 2 | ||||||||
| 1 | FGD5 | 3p25.1 | 19 (15.32%) | 226 (2.19%) | 2.81 | 6.99 × 10−11 | 7.60 × 10−7 | Altered group |
| 2 | MMS22L | 6q16.1 | 17 (13.71%) | 178 (1.73%) | 2.99 | 1.23 × 10−10 | 7.60 × 10−7 | Altered group |
| 3 | LRP5 | 11q13.2 | 19 (15.32%) | 237 (2.30%) | 2.74 | 1.49 × 10−10 | 7.60 × 10−7 | Altered group |
| 4 | PALM2-AKAP2 | 9q31.3 | 17 (13.71%) | 181 (1.76%) | 2.97 | 1.56 × 10−10 | 7.60 × 10−7 | Altered group |
| 5 | GTF3C2 | 2p23.3 | 15 (12.10%) | 135 (1.31%) | 3.21 | 2.37 × 10−10 | 7.67 × 10−7 | Altered group |
| 6 | PAX8 | 2q14.1 | 12 (9.68%) | 72 (0.70%) | 3.79 | 2.53 × 10−10 | 7.67 × 10−7 | Altered group |
| 7 | MFHAS1 | 8p23.1 | 13 (10.48%) | 93 (0.90%) | 3.54 | 3.11 × 10−10 | 7.67 × 10−7 | Altered group |
| 8 | SENP5 | 3q29 | 13 (10.48%) | 94 (0.91%) | 3.52 | 3.51 × 10−10 | 7.67 × 10−7 | Altered group |
| 9 | PRDM9 | 5p14.2 | 25 (20.16%) | 461 (4.47%) | 2.17 | 3.86 × 10−10 | 7.67 × 10−7 | Altered group |
| 10 | LRRFIP2 | 3p22.2 | 13 (10.48%) | 95 (0.92%) | 3.51 | 3.95 × 10−10 | 7.67 × 10−7 | Altered group |
| Cyclin Dependent Kinase 4 | ||||||||
| 1 | EGFR | 7p11.2 | 39 (13.68%) | 357 (3.52%) | 1.96 | 2.25 × 10−12 | 4.38 × 10−8 | Altered group |
| 2 | ZNF19 | 16q22.2 | 18 (6.32%) | 73 (0.72%) | 3.13 | 3.28 × 10−11 | 3.19 × 10−7 | Altered group |
| 3 | NUP107 | 12q15 | 19 (6.67%) | 128 (1.26%) | 2.4 | 1.69 × 10−8 | 5.45 × 10−5 | Altered group |
| 4 | KLHL9 | 9p21.3 | 15 (5.26%) | 75 (0.74%) | 2.83 | 1.76× 10−8 | 5.45 × 10−5 | Altered group |
| 5 | ATP13A5 | 3q29 | 25 (8.77%) | 227 (2.24%) | 1.97 | 2.23× 10−8 | 5.45 × 10−5 | Altered group |
| 6 | TENM2 | 5q34 | 35 (12.28%) | 418 (4.12%) | 1.58 | 2.27× 10−8 | 5.45 × 10−5 | Altered group |
| 7 | MYPN | 10q21.3 | 26 (9.12%) | 247 (2.43%) | 1.91 | 2.68× 10−8 | 5.45 × 10−5 | Altered group |
| 8 | B4GALNT1 | 12q13.3 | 15 (5.26%) | 78 (0.77%) | 2.78 | 2.79× 10−08 | 5.45 × 10−05 | Altered group |
| 9 | PTPRH | 19q13.42 | 24 (8.42%) | 214 (2.11%) | 2 | 3.15× 10−08 | 5.45 × 10−05 | Altered group |
| 10 | NEMF | 14q21.3 | 18 (6.32%) | 120 (1.18%) | 2.42 | 3.53× 10−08 | 5.45 × 10−05 | Altered group |
| Cyclin Dependent Kinase 6 | ||||||||
| 1 | TP53 | 17p13.1 | 159 (62.6%) | 3680 (36.14%) | 0.79 | 2.75 × 10−17 | 5.35 × 10−13 | Altered group |
| 2 | CFAP47 | Xp21.1 | 43 (16.93%) | 399 (3.92%) | 2.11 | 3.41 × 10−15 | 3.31 × 10−11 | Altered group |
| 3 | CUBN | 10p13 | 51 (20.08%) | 625 (6.14%) | 1.71 | 2.03 × 10−13 | 1.31 × 10−9 | Altered group |
| 4 | KBTBD7 | 13q14.11 | 20 (7.87%) | 81 (0.80%) | 3.31 | 2.90 × 10−13 | 1.41 × 10−9 | Altered group |
| 5 | EYS | 6q12 | 39 (15.35%) | 385 (3.78%) | 2.02 | 4.73 × 10−13 | 1.84 × 10−9 | Altered group |
| 6 | FAT3 | 11q14.3 | 59 (23.23%) | 839 (8.24%) | 1.5 | 7.48 × 10−13 | 2.23 × 10−9 | Altered group |
| 7 | SPTBN4 | 19q13.2 | 34 (13.39%) | 298 (2.93%) | 2.19 | 8.39 × 10−13 | 2.23 × 10−9 | Altered group |
| 8 | TCERG1L | 10q26.3 | 21 (8.27%) | 99 (0.97%) | 3.09 | 9.29 × 10−13 | 2.23 × 10−9 | Altered group |
| 9 | ATP2B1 | 12q21.33 | 25 (9.84%) | 153 (1.50%) | 2.71 | 1.03 × 10−12 | 2.23 × 10−9 | Altered group |
| 10 | UBA6 | 4q13.2 | 24 (9.45%) | 141 (1.38%) | 2.77 | 1.38 × 10−12 | 2.68 × 10−9 | Altered group |
| Signal Transducer and Activator of Transcription 3 | ||||||||
| 1 | NEURL4 | 17p13.1 | 39 (17.89%) | 177 (1.73%) | 3.37 | 5.90 × 10−26 | 1.15 × 10−21 | Altered group |
| 2 | ARHGAP5 | 14q12 | 38 (17.43%) | 202 (1.98%) | 3.14 | 3.78 × 10−23 | 3.67 × 10−19 | Altered group |
| 3 | DSG1 | 18q12.1 | 38 (17.43%) | 208 (2.04%) | 3.1 | 9.42 × 10−23 | 6.10 × 10−19 | Altered group |
| 4 | PCDHGB6 | 5q31.3 | 34 (15.60%) | 157 (1.54%) | 3.34 | 1.81 × 10−22 | 8.80 × 10−19 | Altered group |
| 5 | CEP350 | 1q25.2 | 44 (20.18%) | 318 (3.11%) | 2.7 | 5.68 × 10−22 | 2.21 × 10−18 | Altered group |
| 6 | MED13 | 17q23.2 | 40 (18.35%) | 255 (2.50%) | 2.88 | 9.18 × 10−22 | 2.97 × 10−18 | Altered group |
| 7 | HMCN1 | 1q25.3 | 67 (30.73%) | 846 (8.28%) | 1.89 | 5.92 × 10−21 | 1.64 × 10−17 | Altered group |
| 8 | DOCK8 | 9p24.3 | 39 (17.89%) | 255 (2.50%) | 2.84 | 7.08 × 10−21 | 1.72 × 10−17 | Altered group |
| 9 | DNMBP | 10q24.2 | 34 (15.60%) | 180 (1.76%) | 3.15 | 8.24 × 10−21 | 1.78 × 10−17 | Altered group |
| 10 | MAP1B | 5q13.2 | 40 (18.35%) | 277 (2.71%) | 2.76 | 1.37 × 10−20 | 2.65 × 10−17 | Altered group |